The effect of L-arabinose on glycaemic responses in subjects at risk of developing type II diabetes

Completed

• Conditions: 10018424; Diabetes type 2; metabolic diseases

• Registration Number: NL-OMON45845
• Lead Sponsor: Wageningen Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 18

Inclusion Criteria

* Age between 55-80 years
* BMI * 25.0 kg/m2
* Impaired fasting glucose (IFG; fasting glucose * 5.6 and < 7.0 mmol/L) or
* HbA1C: * 39 < 49 mmol/mol

Exclusion Criteria

* Diagnosed diabetes,
* Diagnosed liver, pancreas or endocrine diseases which could affect the study results,
* Having gastro-intestinal problems,
* Use of medication or supplements which could affect the study results (Moreover, chronic medication and supplements should be used as normal when they donot affect the study results),
* Allergy, intolerance or oversensitivity for food products,
* Sensitive to medical skin adhesives,
* Following a medically prescribed, low energy or low carbohydrate diet,
* Unwilling to consume the provided diets,
* >5 kg weight change during the last 3 months,
* Current antibiotics usage or in the two months prior to the screening session,
* Excessive alcohol consumption (>21 glasses/week on average for men and >14 glasses/week for women),
* Having blood vessels that are too difficult for inserting a cannula, as judged by the study nurse,
* Not normal haemoglobin (Hb) concentration: <8.5 mmol/L for men and <7.5 mmol/L for women,
* Recent blood donation (<1 month prior to the first study day),
* Planning to donate blood as a blood donor during the study,
* Mental status that is incompatible with the conduct of the study,
* Being an employee of Wageningen University, division of Human Nutrition and Health,
* Current participation in other research (except EetMeetWeet).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Glycaemic response</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Insulin response, glucagon response, satiety response, glucose monitoring,<br /><br>gastro-intestinal tolerance</p><br>